Clinical factor-based risk stratification for precision therapy in locally advanced squamous cell carcinoma of the uterine cervix

Feng Yuan Liu, Wei Chun Chen, Yu Bin Pan, Chun Chieh Wang, Yun Hsin Tang, Hung Hsueh Chou, Angel Chao, Lan Yan Yang*, Chyong Huey Lai*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review


BACKGROUND: Concurrent chemoradiotherapy (CCRT) is the standard of care for locally advanced cervical cancer. In this study, we analyzed the pretreatment clinical and 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) characteristics of patients with locally advanced cervical squamous cell carcinoma (SCC) to develop a scoring prototype for risk stratification.

METHODS: Two cohorts were constructed in this study. Cohort 1 comprised patients with cervical SCC with 2009 FIGO stage III-IVA or stage I-II with positive pelvic or para-aortic lymph node (PALN) on PET/CT from AGOG09-001 trial. Cohort 2 comprised patients with similar characteristics who had received adequate therapy in our hospital between 2016 and 2021. Pretreatment patient characteristics and PET/CT parameters including maximum standardized uptake value (SUV max ) and metabolic tumor volume (MTV) of primary tumor and nodal SUV max were assessed for cancer-specific survival (CSS) using multivariate Cox regression.

RESULTS: Analysis of combined data from cohorts 1 (n = 55) and 2 (n = 128) indicated age ≥ 66 years, primary tumor MTV ≥87 mL, and positive PALN on PET/CT to be independently significant adverse predictors for CSS (p < 0.001, p = 0.014, and p = 0.026, respectively) with a median follow-up duration of 51 months. Assigning a score of 1 to each adverse predictor, patients with cumulative risk scores of 0, 1, 2, and 3 were discovered to have a 5-year CSS of 86.9%, 71.0%, 32.2%, and 0%, respectively (p < 0.001).

CONCLUSION: Age, primary tumor MTV, and positive PALN on PET/CT may serve as independent predictors of poor survival in patients with locally advanced cervical SCC. Our findings indicate that patients without any adverse factors can receive standard CCRT, whereas those with at least one adverse factor can consider novel combination therapies or clinical trials.

Original languageEnglish
Article numbere6746
JournalCancer Medicine
Issue number1
Early online date08 01 2024
StatePublished - 01 2024

Bibliographical note

© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.


  • concurrent chemoradiotherapy
  • locally advanced cervical cancer
  • risk stratification
  • squamous cell carcinoma


Dive into the research topics of 'Clinical factor-based risk stratification for precision therapy in locally advanced squamous cell carcinoma of the uterine cervix'. Together they form a unique fingerprint.

Cite this